{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T08:54:04Z","timestamp":1764060844340,"version":"3.37.3"},"reference-count":109,"publisher":"Informa UK Limited","issue":"4","funder":[{"name":"supported in part by Retrosolutions"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2019,3,4]]},"DOI":"10.1080\/14656566.2018.1560423","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T14:10:05Z","timestamp":1548857405000},"page":"385-397","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":19,"title":["Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications"],"prefix":"10.1080","volume":"20","author":[{"given":"Hanh Thi","family":"Pham","sequence":"first","affiliation":[{"name":"Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University AIDS Centre, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Department of Microbiology and Immunology, Faculty of Medicine, McGill University, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0515-9128","authenticated-orcid":false,"given":"Thibault","family":"Mespl\u00e8de","sequence":"additional","affiliation":[{"name":"Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University AIDS Centre, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Department of Microbiology and Immunology, Faculty of Medicine, McGill University, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Division of Experimental Medicine, Faculty of Medicine, McGill University, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Division of Infectious Diseases, Jewish General Hospital, McGill University, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2019,1,30]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30702-8"},{"key":"CIT0002","unstructured":"Hiv drug resistance report. World Health Organization, United States Centers for Disease Control and Prevention, The Global Fund to Fight AIDS, Tuberculosis and Malaria; 2017."},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1002251"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00915-10"},{"journal-title":"J Infect Dis","year":"2018","author":"Achieng L","key":"CIT0005"},{"journal-title":"J Infect Dis","year":"2018","author":"Pham HT","key":"CIT0006"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy428"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy229.2178"},{"volume-title":"Guidelines for the use of antiretroviral agents in hiv-1-infected adults and adolescents","year":"2018","key":"CIT0009"},{"volume-title":"Brown T. Fda approves ibalizumab for multidrug-resistant hiv-1","year":"2018","key":"CIT0010"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1808729"},{"volume-title":"Antiviral activity of efda against nrti-sensitive and -resistant strains of hiv-2","year":"2017","author":"Vincent W","key":"CIT0012"},{"volume-title":"Mk-8591 concentrations at sites of hiv transmission and reduction","year":"2017","author":"Jay G","key":"CIT0013"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000469"},{"volume-title":"EACS Conference","year":"2017","author":"Kozal M","key":"CIT0015"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1021\/jm800245z"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.17.1.97"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1086\/650002"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318157131c"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60597-2"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1086\/597290"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318298469c"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1086\/650698"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283473599"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318286415c"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318289545c"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000089"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000057"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-017-0360-7"},{"issue":"1","key":"CIT0030","first-page":"177","volume":"73","author":"Castagna A","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis750"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2878"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu051"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03485-14"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3275"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30152-2"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy175"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-018-0440-3"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31917-7"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000480"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2018.1460357"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2018.1430570"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000168"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02885-x"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.8431"},{"key":"CIT0046","unstructured":"Gilead. Biktarvy\u00ae (bictegravir, emtricitabine, and tenofovir alafenamide) tablets, for oral use. Initial u.S. Approval. 2018."},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0896-4"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1254\/fpj.150.251"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1177\/1060028016660812"},{"volume-title":"Elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide (evg\/cobi\/ftc\/taf) (genvoya) fixed-dose combination, oral tablet","year":"2016","key":"CIT0050"},{"issue":"12","key":"CIT0051","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","volume":"60","author":"Tsiang M","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01834-15"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000225"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.035"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.1898-1906.2005"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61221-0"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01168-09"},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06170-11"},{"key":"CIT0059","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06618-11"},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3033"},{"key":"CIT0061","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-018-0420-7"},{"key":"CIT0062","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy428"},{"issue":"10107","key":"CIT0063","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","volume":"390","author":"Sax PE","year":"2017","journal-title":"Lancet"},{"key":"CIT0064","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32299-7"},{"volume-title":"Resistance analyses of bictegravir\/emtricitabine\/tenofovir alafenamide switch studies","year":"2018","author":"Kristen A","key":"CIT0065"},{"volume-title":"International AIDS Conference","year":"2018","author":"Acosta RK","key":"CIT0066"},{"volume-title":"Pooled week 48 efficacy and baseline resistance: B\/f\/taf in treatment-naive patients","year":"2018","author":"Kirsten W","key":"CIT0067"},{"volume-title":"Integrase inhibitor resistance selections initiated with drug resistant hiv-1","year":"2018","author":"Kristen A","key":"CIT0068"},{"volume-title":"In vitro selected resistance to new integrase inhibitors by b and non-b subtype viruses","year":"2018","author":"Bluma BG","key":"CIT0069"},{"key":"CIT0070","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2009.0249"},{"issue":"4","key":"CIT0071","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/135965350701200411","volume":"12","author":"Lataillade M","year":"2007","journal-title":"Antivir Ther"},{"key":"CIT0072","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0402357101"},{"key":"CIT0073","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70257-3"},{"key":"CIT0074","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy176"},{"key":"CIT0075","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw186"},{"key":"CIT0076","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix1083"},{"key":"CIT0077","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06591-11"},{"key":"CIT0078","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx118"},{"issue":"7","key":"CIT0079","volume":"11","author":"Wares M","year":"2014","journal-title":"Retrovirology"},{"key":"CIT0080","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx475"},{"issue":"3","key":"CIT0081","first-page":"850","volume":"72","author":"Stefic K","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"CIT0082","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22914-5"},{"key":"CIT0083","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000752"},{"key":"CIT0084","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2018.06.012"},{"volume-title":"22nd International AIDS Conference","year":"2018","author":"Acosta R","key":"CIT0085"},{"key":"CIT0086","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01035-18"},{"key":"CIT0087","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit697"},{"key":"CIT0088","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001306"},{"key":"CIT0089","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30016-4"},{"key":"CIT0090","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001894"},{"key":"CIT0091","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4379"},{"volume-title":"Bictegravir\/ftc\/taf single-tablet regimen in adolescents: week-24 results.","year":"2018","author":"Aditya GH","key":"CIT0092"},{"volume-title":"Clinical pharmacology of the hiv integrase strand transfer inhibitor bictegravir","year":"2017","author":"Heather Z","key":"CIT0093"},{"journal-title":"HIV Drug Ther","year":"2018","author":"Podzamczer D","key":"CIT0094"},{"journal-title":"HIV Drug Ther","year":"2018","author":"Stellbrink HJ","key":"CIT0095"},{"issue":"7","key":"CIT0096","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","volume":"5","author":"Molina JM","year":"2018","journal-title":"Lancet HIV"},{"issue":"5","key":"CIT0097","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s40271-018-0322-8","volume":"11","author":"Wohl D","year":"2018","journal-title":"Patient"},{"key":"CIT0098","unstructured":"Andreatta K, Haubrich R, Willkom M, et al. High prevalence of previously undocumented baseline m184v\/i does not affect virologic outcome in virologically-suppressed patients switching to bictegravir\/emtricitabine\/tenofovir\/alafenamide (b\/f\/taf) from a boosted protease inhibitor-based regimen. HIV Drug Ther. 2018. Glassgow, UK."},{"issue":"7","key":"CIT0099","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/S2352-3018(18)30091-2","volume":"5","author":"Daar ES","year":"2018","journal-title":"Lancet HIV"},{"volume-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide in women","year":"2018","author":"Kityo C","key":"CIT0100"},{"key":"CIT0101","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.1082"},{"volume-title":"Pharmacokinetics of bictegravir administered twice daily in combination with rifampin","year":"2018","author":"Joseph CM","key":"CIT0102"},{"key":"CIT0103","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001699"},{"key":"CIT0104","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052562"},{"key":"CIT0105","unstructured":"Panel on treatment of pregnant women with hiv infection and prevention of perinatal transmission. Recommendations for use of antiretroviral drugs in transmission in the united states. U.S. Department of Health and Human Services; 2018. AIDSinfo website: https:\/\/aidsinfo.nih.gov\/guidelines."},{"key":"CIT0106","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1807653"},{"volume-title":"Surveillance for neural tube defects following antiretroviral exposure from conception","year":"2018","author":"Rebecca Z","key":"CIT0107"},{"issue":"2","key":"CIT0108","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S2055-6640(20)30247-8","volume":"4","author":"Hill A","year":"2018","journal-title":"J Virus Erad"},{"journal-title":"HIV Drug Ther.","year":"2018","author":"Farrow T","key":"CIT0109"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2018.1560423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T04:16:48Z","timestamp":1662869808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2018.1560423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,30]]},"references-count":109,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,3,4]]}},"alternative-id":["10.1080\/14656566.2018.1560423"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2018.1560423","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"type":"print","value":"1465-6566"},{"type":"electronic","value":"1744-7666"}],"subject":[],"published":{"date-parts":[[2019,1,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-08-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}